Latest revision as of 20:57, 13 January 2011

The Project	Background	Design	Parts Submitted to the Registry	Notebook	The Team	Outreach & Human Practices	Safety	Application

OMG OMVs!

Outer membrane vesicles (OMVs) are natural secretions by gram-negative bacteria that can transport various proteins, lipids, and nucleic acids in interactions with mammalian host cells. OMV technology presents an affordable, non-toxic, and direct method of drug delivery and antigen tracking. We have designed a method for visualizing the interactions of mammalian cells with outer membrane vesicles by utilizing the ClyA surface protein as an attachment site for fluorescent proteins. The current goal of this project is to characterize the distribution of varying ClyA-fluorescent protein complexes on OMVs. Future work will be to develop a tracking system employing two ClyA constructs: a ClyA-fluorescent protein fusion for in vitro microscope imaging and a ClyA-single-chain antibody fragment to bind to an antigen.

@@ Line 10: / Line 10: @@
 !align="center"|[[Team:Cornell/Team|The Team]]
 !align="center"|[[Team:Cornell/Outreach & Human Practices|Outreach & Human Practices]]
+!align="center"|[[Team:Cornell/Safety|Safety]]
+!align="center"|[[Team:Cornell/Application|Application]]
 |}
@@ Line 25: / Line 27: @@
 as an attachment site for fluorescent proteins. The current goal of this project is to
 characterize the distribution of varying ClyA-fluorescent protein complexes on OMVs.
-Future work will be to develop a tracking system employing a ClyA-fluorescent protein
+Future work will be to develop a tracking system employing two ClyA constructs:  a ClyA-fluorescent protein
-construct for in vitro microscope imaging. An antibody fragment will also be attached to
+fusion for in vitro microscope imaging and a ClyA-single-chain antibody fragment to bind to an antigen.
-another ClyA complex, allowing the OMV tracking system to target specific regions of
-an organism. This method allows in vitro characterization of OMVs and provides integral
-data for developing a future OMV delivery platform in vivo.